Ir para o conteúdo principal

Coya Therapeutics (NASDAQ: COYA) — Perfil da empresa, notícias e dados financeiros

Logo de Coya Therapeutics
COYA Coya Therapeutics
Coya Therapeutics  primary media
Perfil da empresa

Coya Therapeutics

Coya Therapeutics (NASDAQ:COYA) focuses on developing innovative therapies aimed at combating a wide range of autoimmune, neurodegenerative, and aging-related diseases. By harnessing the power of regulatory T cells (Tregs) and leveraging advanced biotechnological processes, Coya Therapeutics aims to pave new pathways in the treatment of conditions like ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, and systemic lupus erythematosus (SLE). Central to their mission is the commitment to advancing clinical research, with several key projects in various stages of development aimed at unlocking the therapeutic potential of Tregs. Their objectives include not only advancing the science behind autoimmune and neurodegenerative disease treatments but also improving the quality of life for patients suffering from these challenging conditions.

Resumo

Public USParticipação acionária
2020Ano de fundação
8Funcionários
Houston, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Houston, US

Produtos e/ou serviços de Coya Therapeutics

  • Development of therapeutic treatments focused on neurodegenerative diseases such as ALS and Alzheimer's.
  • Research on anti-inflammatory therapeutics for autoimmune disorders.
  • Innovative approaches to enhancing the bioavailability of treatments for better patient outcomes.
  • Collaborations with academic institutions for advanced research in neurology and immunology.
  • Engagement in clinical trials to validate the efficacy and safety of new drugs and therapies.
  • Leveraging proprietary technology platforms to discover novel therapeutic targets.

equipe executiva do Coya Therapeutics

  • Arun SwaminathanCEO & Director
  • Fred GrossmanPresident & Chief Medical Officer
  • David S. SnyderCFO & COO
  • Aaron ThomeHead of Neuroinflammation Platform
  • Michelle FrazierSenior Vice President of Regulatory
  • Karen KingSenior VP of Program Management & Clinical Operations

Principais indicadores financeiros

Resultados divulgados pela Coya Therapeutics , em USD.

Cap. de mercado
95,2 mi
Receita (TTM)
8 mi
P/L
—
LPA (diluído, TTM)
-1.1
Dividend yield
—
Margem de lucro
-270.2%
Receita e lucro anuais da Coya Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
7,9 mi-20,3 mi-21,2 mi
3,6 mi-17,2 mi-14,9 mi
6 mi-7,9 mi-8 mi
0-9,8 mi-12,2 mi